로그인시 본인확인과정이 필요할 수 있습니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기
| 국가/구분 | United States(US) Patent 등록 |
|---|---|
| 국제특허분류(IPC7판) |
|
| 출원번호 | US-0941008 (2001-08-28) |
| 발명자 / 주소 |
|
| 출원인 / 주소 |
|
| 대리인 / 주소 |
|
| 인용정보 | 피인용 횟수 : 705 인용 특허 : 26 |
An anastomosis staple comprising of a plurality of vessel engaging members and a binding structure holding the vessel engaging members together is described. The binding structure has at least one bioabsorbable element. The binding structure is rigid enough to allow for deployment and quickly resorb
An anastomosis staple comprising of a plurality of vessel engaging members and a binding structure holding the vessel engaging members together is described. The binding structure has at least one bioabsorbable element. The binding structure is rigid enough to allow for deployment and quickly resorbs to avoid problems associated with intimal hyperplasia and physical hindrance of secondary interventional procedures. The vessel engaging members may be comprised of superelastic or shape memory metal and are independent from one another. The members may be equidistant from one another and embedded within the binding structure. The composite staple can preferably serve as a drug delivery vehicle.
An anastomosis staple comprising of a plurality of vessel engaging members and a binding structure holding the vessel engaging members together is described. The binding structure has at least one bioabsorbable element. The binding structure is rigid enough to allow for deployment and quickly resorb
An anastomosis staple comprising of a plurality of vessel engaging members and a binding structure holding the vessel engaging members together is described. The binding structure has at least one bioabsorbable element. The binding structure is rigid enough to allow for deployment and quickly resorbs to avoid problems associated with intimal hyperplasia and physical hindrance of secondary interventional procedures. The vessel engaging members may be comprised of superelastic or shape memory metal and are independent from one another. The members may be equidistant from one another and embedded within the binding structure. The composite staple can preferably serve as a drug delivery vehicle. ng implantation of an intraocular lens (IOL), and wherein the anterior chamber of the eye is filled with the activating solution after the extraction and implantation, or the eye is irrigated with the activating solution in an amount of 20-200 ml during the extraction and implantation. 5. The method according to claim 1, wherein to reduce the loss of endothelium cells after an operation, the activating solution is administered subconjunctivally in an amount of 0.3 ml daily for 3-5 days. 6. The method according to claim 1, wherein the activating solution is administered subconjunctivally in the eye, in an amount of 0.3 ml daily for 5-10 days or by phonophoresis through the cornea in a continuous mode for 10 minutes at an intensity of 0.2-0.3 W/cm2with use of 5 ml of the solution daily. 7. The method according to claim 1, wherein at an initial stage of an ocular operation the anterior chamber of the eye is filled with an activating solution further comprising a viscoelastic in an amount of 90-99% by weight. 8. The method according to claim 2, wherein the activating solution is administered during an extraction of a cataract with implantation of an intraocular lens (IOL) or during implantation of an intraocular lens (IOL) for refraction, and wherein the anterior chamber of the eye is filled with the activating solution after the extraction and implantation, or the eye is irrigated with the activating solution in an amount of 20-200 ml is carried out during the extraction and implantation. 9. The method according to claim 3, wherein the activating solution is administered during an extraction of a cataract with implantation of an intraocular lens (IOL) or during implantation of an intraocular lens (IOL) for refraction, and wherein the anterior chamber of the eye is filled with the activating solution after the extraction and implantation, or the eye is irrigated with the activating solution in an amount of 20-200 ml during the extraction and implantation. 10. The method according to claim 2, wherein to reduce the loss of endothelium cells after an operation, the activating solution is administered subconjunctivally in an amount of 0.3 ml daily for 3-5 days. 11. The method according to claim 3, wherein to reduce the loss of endothelium cells after an operation, the activating solution is administered subconjunctivally in an amount of 0.3 ml daily for 3-5 days. 12. The method according to claim 6, wherein the eye is keratopathic. 13. The method according to claim 6, wherein the activating solution is administered by phonophoresis and the administration is repeated 5 to 8 times. 14. The method according to claim 2, wherein the activating solution is administered subconjunctivally in the eye, in an amount of 0.3 ml daily for 5-10 days or by phonophoresis through the cornea in a continuous mode for 10 minutes at an intensity of 0.2-0.3 W/cm2with use of 5 ml of the solution daily. 15. The method according to claim 14, wherein the eye is keratopathic. 16. The method according to claim 15, wherein the activating solution is administered by phonophoresis and the administration is repeated 5 to 8 times. 17. The method according to claim 3, wherein the activating solution is administered subconjunctivally in the eye, in an amount of 0.3 ml daily for 5-10 days or by phonophoresis through the cornea in a continuous mode for 10 minutes at an intensity of 0.2-0.3 W/cm with use of 5 ml of the solution daily. 18. The method according to claim 17, wherein the eye is keratopathic. 19. The method according to claim 17, wherein the activating solution is administered by phonophoresis and the administration is repeated 5 to 8 times. 20. The method according to claim 1, wherein the activating solution is administered subconjunctivally in the eye, and the eye is developing secondary endothelium-epithelium dystrophy, in an amount of 0.3 ml daily for 5-10 days or by phonophoresis through the cornea in a continuous mode for 10 minutes at an intensity of 0.2-0.3 W/cm2with use of 5 ml of the solution daily. 21. The method according to claim 20, wherein the activating solution is administered by phonophoresis and the administration is repeated 5 to 8 times. 22. The method according to claim 2, wherein the activating solution is administered subconjunctivally in the eye, and the eye is developing secondary endothelium-epithelium dystrophy, in an amount of 0.3 ml daily for 5-10 days or by phonophoresis through the cornea in a continuous mode for 10 minutes at an intensity of 0.2-0.3 W/cm2with use of 5 ml of the solution daily. 23. The method according to claim 22, wherein the activating solution is administered by phonophoresis and the administration is repeated 5 to 8 times. 24. The method according to claim 3, wherein the activating solution is administered subconjunctivally in the eye, and the eye is developing secondary endothelium-epithelium dystrophy, in an amount of 0.3 ml daily for 5-10 days or by phonophoresis through the cornea in a continuous mode for 10 minutes at an intensity of 0.2-0.3 W/cm2with use of 5 ml of the solution daily. 25. The method according to claim 24, wherein the activating solution is administered by phonophoresis and the administration is repeated 5 to 8 times. 26. The method according to claim 2, wherein a 0.001-0.01 M phosphate buffer with a pH of 7.2-7.6 in a 0.14-0.16 M solution of sodium chloride is used as the balanced salt solution. 27. The method according to claim 2, wherein at an initial stage of an ocular operation the anterior chamber of the eye is filled with an activating solution further comprising a viscoelastic in an amount of 90-99% by weight. 28. The method according to claim 3, wherein at an initial stage of an ocular operation the anterior chamber of the eye is filled with an activating solution further comprising a viscoelastic in an amount of 90-99% by weight. 29. The method according to claim 26, wherein the activating solution is administered during an extraction of a cataract with implantation of an intraocular lens (IOL) for refraction or during implantation of an intraocular lens (IOL), and wherein the anterior chamber of the eye is filled with the activating solution after the extraction and implantation, or the eye is irrigated with the activating solution in an amount of 20-200 ml during the extraction and implantation. 30. The method according to claim 26, wherein to reduce the loss of endothelium cells after an operation, the activating solution is administered subconjunctivally in an amount of 0.3 ml daily for 3-5 days. 31. The method according to claim 26, wherein the activating solution is administered subconjunctivally in the eye, in an amount of 0.3 ml daily for 5-10 days or by phonophoresis through the cornea in a continuous mode for 10 minutes at an intensity of 0.2-0.3 W/cm2with use of 5 ml of the solution daily. 32. The method according to claim 26, wherein at an initial stage of an ocular operation the anterior chamber of the eye is filled with an activating solution further comprising a viscoelastic in an amount of 90-99% by weight. 33. The method according to claim 31, wherein the eye is keratopathic. 34. The method according to claim 31, wherein the activating solution is administered by phonophoresis and the administration is repeated 5 to 8 times. 35. The method according to claim 26, wherein the activating solution is administered subconjunctivally in the eye, and the eye is developing secondary endothelium-epithelium dystrophy, in an amount of 0.3 ml daily for 5-10 days or by phonophoresis through the cornea in a continuous mode for 10 minutes at an intensity of 0.2-0.3 W/cm2with use of 5 ml of the solution daily. 36. The method according to claim 35, wherein the activating solution is administered by phonophoresis and the administration is repeated 5 to 8 times. alian skin through a hair duct, the process comprising: selecting at least one of a photoactive agent and a photo sensitizing agent, the agent having an average diameter enabling the agent to penetrate the hair duct, the agent having an electromagnetic radiation absorption characteristic enabling the agent to absorb at least a first wavelength of electromagnetic radiation from a skin-penetrating electromagnetic radiation source, applying the agent to the hair and skin, forming an agent-tissue complex by a process comprising reacting the agent with cells in the hair, the skin, or both, and exposing the agent-tissue complex to incoherent, multi-frequency electromagnetic radiation comprising at least the first wavelength of electromagnetic radiation, whereby the agent-tissue complex absorbs the first wavelength of electromagnetic radiation. 2. The process of claim 1, comprising the step of exposing at least one of the skin and hair to at least one external enzyme. 3. The process of claim 1, comprising the step of exposing at least one of the skin and hair to ultrasound. 4. The process of claim 1, wherein the step of exposing the agent to at least a first wavelength of electromagnetic radiation comprises exposing the agent to electromagnetic radiation from at least one of a diode laser, a light emitting diode, a filamentous incoherent light source and a non-laser light source. eps of: providing a gas conduit including at least two electrodes; delivering at least one pulse of radio frequency power to at least one of said electrodes to create an electric field between at least two said electrodes; passing gas through said electric field in order to form plasma from said gas; and emitting said plasma from the gas conduit such that it is applied to the surface of skin, such that the application of plasma to the surface of skin causes denaturation of collagen with collagen-containing tissue beneath the skin surface, wherein said at least one pulse of radio frequency power has an energy such as to produce a temperature rise of up to 22.7° C. under the copper disc test. 17. A method according to claim 16, wherein the generation of new collagen within said collagen-containing tissue is promoted. 18. A method according to claim 16, wherein said at least one pulse of radio frequency power has an energy such as to produce a temperature rise of between 12.8° C. and 19.4° C. under the copper disc test. 19. A method according to claim 16, wherein said at least one pulse has a duration in the range of from 5 ms to 20 ms. 20. A method according to claim 16, wherein a series of pulses of plasma are applied to a series of regions of the skin surface. 21. A method according to claim 20, wherein said regions of the skin surface overlap. 22. A method according to claim 20, wherein one of said series of pulses is applied to each said region of the skin surface. 23. A method according to claim 20, wherein at least two pulses of plasma are applied to each of said regions of the skin surface. 24. A method according to claim 23, wherein said at least two pulses of plasma are applied to each region consecutively. 25. A method according to claim 24, wherein one pulse of plasma is applied to each of said regions of the skin surface before a second pulse of plasma is applied to each of said regions.
해당 특허가 속한 카테고리에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.